PIH19 Cost-Effectiveness of Nexplanon® (Etonogestrel Implant) Compared to other Reimbursed Contraceptive Methods in France Based on Real Life Data  by Lafuma, A et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A735
and available e-library resources considering the associated preventing drug related 
problems and Healthcare Improvement and better care, better patient outcomes, 
and reduced costs.
PIH17
EconomIc ImPact of trEatIng cHInEsE PostmEnoPausal WomEn 
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Objectives: In China there is a lack of awareness of HRT as a treatment option to alle-
viate climacteric symptoms apart from herbal or traditional Chinese medicines (CM). 
This study aims to assess economic impact of reimbursing 17-ß-estradiol combined 
HRT from Chinese payer’s perspective. MethOds: An economic analysis based on 
Danish Osteoporosis Prevention Study (DOPS) efficacy data was conducted to model 
an assumptive cohort of 100,000 women in 2 comparisons, namely HRT based on 2mg 
17-ß-estradiol and 10 mg Dydrogesterone versus mixed-treatment cohort, (including 
41% no treatment after clinical consultations and 59% treated using CM), and a second 
comparison of HRT versus 100% CM (50,000 for each group). Long-term fracture, car-
diovascular (CV) events and drug procurement costs are evaluated as main outcomes. 
Cost data are obtained from Shanghai Patient Electronic Medical Records. Daily drug 
cost is ¥4.39 for HRT based on the only available 17-ß-estradiol included combina-
tion drug in China and ¥12 for alternative treatment based on the market research. 
5-year continuous treatments with 65% compliance and 10% patients’ copayment 
are reported as base-case scenario. Results: The per person costs to achieve frac-
ture free 5 year for HRT, CM-59%, and CM-100% cohorts was ¥831, ¥1,370, and ¥2,276, 
respectively. The cost per CV event free 5 year for HRT, CM-59%, and CM-100% cohorts 
was ¥814, ¥1,363, and ¥2,275, respectively. The cost savings achieved with HRT com-
pared to CM-59%, and CM-100% cohorts was ¥544 and ¥1453, respectively. Comparing 
the costs for 50,000 women using HRT with CM-59%, and CM-100%, a savings of ¥143 
million and ¥369 million, respectively was achieved. cOnclusiOns: Although the 
willingness for Chinese menopausal women to seek treatment is quite low, treating 
all those who have sought clinical consultations with HRT rather than maintaining 
use of CM may save healthcare expenditure.
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Objectives: Bemfola, biosimilar follitropin alfa, has been launched in the 
Italian Market as a treatment for infertility. The aim of this project is to perform 
a cost-effectiveness evaluation comparing Bemfola to Gonal-f in an Italian con-
test. MethOds: Starting from “A multi-centre phase 3 study comparing efficacy 
and safety of Bemfola® versus Gonal-f in women undergoing ovarian stimulation 
for IVF” by Rettenbacher et al., a cost-effectiveness model was developed to compare 
costs and efficacies of the two comparators (Bemfola and Gonal-f) in an Italian 
contest. Clinical data on number of subjects, total dose of gonadotropins, pregnan-
cies and liveborn children, OHSS for both first and second cycle of the study by 
Rettenbacher et al. were used to feed the model. Costs related to drugs, DRG for ART, 
specialistic visits and examinations were retrieved from 2015 Italian tariffs. The 
perspective is the NHS one. Costs of Bemfola and Gonal-f arms were divided by the 
efficacies, i.e. live birth rate, in order to obtain an average cost per live birth and ICER 
was also calculated. Results: Gonal-f cost resulted to be € 3,550 whereas Bemfola 
cost resulted to be € 3,483. Efficacy, i.e. live birth rate, associated to Gonal-f was 0.52 
whereas it was 0.47 for Bemfola. The average cost per live birth was estimated to 
be € 6,787 for Gonal-f and € 7,449 for Bemfola. Furthermore, Gonal-f generated an 
ICER equal to € 1,210 compared to Bemfola, which is the additional cost required 
for Gonal-f to gain an additional live birth in comparison with Bemfola. Gonal-f, 
although it has a higher acquisition cost in comparison with Bemfola, provides a 
lower average cost per live birth and an ICER of € 1,210. cOnclusiOns: The results 
of this cost-effectiveness analysis indicate that Gonal-f is a cost-efficient treat-
ment strategy for the Italian health service compared to Bemfola in the treatment 
of infertility.
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Objectives: To estimate the cost-effectiveness of Nexplanon (etonogestrel 
implant) compared to other reimbursed contraceptive methods in 
France. MethOds: A 6 year cost effectiveness model was developed to assess the 
cost per unplanned pregnancy of different reimbursed methods (oral contracep-
tive pill (COC), hormonal intrauterine device (IUD), copper IUD and Nexplanon® 
among French women in the perspective of the French health care system. Efficacy 
inputs, including rate of pregnancies and discontinuation, as well as economic 
parameters of the model were estimated through an analysis of French claim 
database named EGB based on 2012 data (FACET study). Outcomes considered 
for contraceptive failure were birth, extra-uterine pregnancy, miscarriage and 
abortion. Costs of contraception and failures included device, drugs, exams and 
medical management (physician visits, procedures and hospitalizations) as 
reported in the database. A discount rate of 4% was applied to both efficacy and 
Objectives: At the most European countries the cost for assisted reproduc-
tive technology (ART) are compensated from state and insurance funds. At the 
first in Ukraine state funding of ART was launched on the Orders of MoH №579 
from 24.11.2004. However, most patients have to pay own out-of-pocket costs for 
ART. MethOds: We evaluated the general cost of short and long stimulation pro-
tocols for ART of new Order of MOH Ukraine №771 from 23.12.2008 “On Approval 
of Instruction on the use of assisted reproductive technologies”. Cost analysis for 
short and long protocols, based on the comparison of costs during 2014 and 2015 in 
Ukraine. Results: We used the prices from database Morion (Kiyv) on 01.04.2015 
and analysed the cost for short protocol. The stimulation of superovulation with 
Puregon was 18000 UAH (1Euro= 24.7 UAH) or with Elonva was 13 000 UAH. Also 
cost on other medicines were included. In average, a general cost per 1 cycle was 
16 600 UAH. Were analyzed the cost of ART long protocol. We included the cost 
with Diferelin depot that was 2800 UAH. The cost of stimulation of superovulation 
with Puregon was 18000 UAH. In average, a general cost per 1 cycle was 24 000 UAH. 
We compared the cost data on ART during 2014-2015. The average salary was 3998 
UAH on 01.04.2015 in Ukraine. cOnclusiOns: Comparing data 2014 and 2015 were 
founded, that the cost of short protocol increased by 27% and by 41% the long one. 
It was established that the cost of ART are high. Revealed that the cost of ART is 4-6 
times higher than the average salary, therefore the availability of ART for families 
is low. It is necessary to determine the budget financing for ART to improve access 
to ART in Ukraine.
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Objectives: Preeclampsia has a high prevalence rate and it’s the second leading 
cause of maternal mortality. In developing countries a preeclampsia is the cause of 
50 000 deaths each year. An effective method of preeclampsia prevention in accord-
ance with WHO guidelines, is a prescription of antiplatelet drugs. MethOds: 
Analysis of consumed drugs for pregnant women, according to the real practice 
of the district hospital in Lviv region during 2014. Systematization of evidence 
data about the effectiveness of prevention and treatment of preeclampsia, which 
were published in the databases Cochrane, Pubmed, ClinicalTrials.gov Results: 
The analysis of 112 medical records pregnant inpatients, who were hospitalized 
in September-December 2014, were conducted. For 42 (38%) patients were diag-
nosed the preeclampsia. For treatment intended antiplatelet drugs for 17 patients 
that only 40% were taking effective treatment. Other patients received various 
vitamins and antioxidants that have not confirmed evidence-effectiveness. The 
analysis of databases showed that recent RCTs (2013) indicate that antiplatelet 
therapy reduced the risk of pre-eclampsia by 21%. In randomize studies found 
that reduced level of neonatal mortality on 16% and the frequency of children 
born with low birth weight on 8%. In Ukraine, were registered 23 trade names of 
aspirin, including 11 from ukranian manufacturers. We calculated the costs of 
prevention during 5 months per patient (1 USD= 22,3 UAH on 30.05.2015). Costs 
ranged from 3,10 USD to 15,5 USD. The best choice of affordable was aspirin in 75 
mg with total costs 4,67 USD. cOnclusiOns: We established that treatment with 
low doses of aspirin 75 mg / day in early pregnancy for women with high risk of 
preeclampsia is an effective prevention of preeclampsia. In Ukraine the patients 
have to pay out of pocket , than the necessary information support of doctors in 
hospitals on effective and affordable prevention of preeclampsia by antiplatelet 
schemes.
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Objectives: National Drug Information Center (NDIC) has started providing ser-
vices since January 2013; and answering public and professional inquires through 
MOH-Hotline Calling Services (937) since December 2013. The objective of this study 
was to estimate cost-efficiency of NDIC in Saudi Arabia using American model 
of drug information inquires cost avoidance. MethOds: Simulation including 
all 12-month 2014 of receiving adults and pediatrics drug information inquiries 
through MOH-Hotline Calling Services (937). Ten on-call clinical Pharmacists and 
expert trained pharmacists were receiving calls from public and professional asking 
about drug information, through manual documentation system of drug informa-
tion inquiries by data collecting form. Using international Study Model (Kinky et 
al, Ann Pharmacother 1999), the cost considered were the expected results of drug 
related problems sequel of drug information inquires if not existing drug infor-
mation services and were not answered; starting from Physician visit, additional 
treatment, hospital admission to death stage. Results: The total number answered 
calls were 976 calls, with 264 (27%) answered calls were documented; the aver-
age costs avoidance per each answered call was (415.78 USD), and total cost was 
(109,768 USD) with partial documentation, the estimated total cost with complete 
documentation was (405,801 USD) per year. The cost avoidance of answering public 
inquiries was (80,806.5 USD) and Professional inquires was (28,961.5 USD). The high-
est cost avoidance based on type of inquires was dose standardization (34,195 USD), 
drug administration (21,324 USD) followed by drugs in pregnancy (15,826 USD) and 
Adverse a Drug reaction (12,793 USD). The highest cost avoidance was Antibacterial 
expected related problem (33,454.5 USD) cOnclusiOns: In this National Drug 
Information Center cost-efficiency simulation for Saudi Arabia, hotline line calling 
services - Drug Information associated with cost savings per each receiving call. 
expanding the answering drug information services with electronic documentation, 
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fracture, vertebral fracture, breast cancer, colorectal cancer, ovarian cancer, coro-
nary heart disease, stroke and venous thromboembolic events. Health states were 
mutually exclusive. Women were followed through a VMS phase and an additional 
post-VMS phase in order to assess the treatment effects on the LTEs, representing a 
life-time horizon. Women were assumed to experience VMS and receive treatment 
for 4 years, additionally, onset of vaginal bleeding or any LTE resulted in treatment 
discontinuation. The model utilized data for treatment effects (estimated via net-
work meta-analyses), risks, mortality, quality of life (QoL – using EQ5D estimates) 
and costs, which were identified from a literature review. The main outcome was 
cost per QALY. Results: Results showed that CE/BZA lead to a gain in QALYs but 
was associated with higher total costs, resulting in a cost per QALY of $12,949 and 
$26,066 when compared with CE/MPA and no treatment, respectively. Driven by 
fewer bleeding events, women on CE/BZA received treatment for a longer duration 
than women receiving CE/MPA. The LTEs impacted results modestly. Uncertainty 
analyses indicated that results were robust to changes in key assumptions and input 
data, however results were most sensitive to changes in QoL associated with VMS 
and vaginal bleeding. cOnclusiOns: CE/BZA is considered cost-effective for the 
treatment of VMS in postmenopausal women when compared with either CE/MPA 
or no treatment in the United States.
PIH24
tHE comParatIvE PHarmacoEconomIc analysIs of usIng 
korIfollItroPIn alfa WItH ganIrElIx and follItroPIn alfa WItH 
cEtrorElIx for ovarIan stImulatIon
Krysanova V1, Krysanov I2, Tolkushin A3
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Postgraduate Medical 
Institute, Moscow National University of Food Production, Moscow, Russia, 3MSD, Moscow, Russia
Objectives: Corifollitropin alfa, a fusion protein, has a longer elimination half-life 
and extended time to peak levels than recombinant FSH (rFSH). The main aim of this 
study was to perform comparative pharmacoeconomic analysis of using korifol-
litropin alfa with ganirelix and follitropin alfa with cetrorelix for ovarian stimula-
tion. MethOds: Analysis of the published clinical trials was conducted to evaluate 
comparative efficacy and safety of the studied therapy options. Direct medical costs 
included drug therapy and hospital treatment. Taking into account the hypothesis 
of equal effectiveness of using korifollitropin alfa with ganirelix and follitropin 
alfa with cetrorelix for ovarian stimulation for pharmacoeconomic analysis was 
chosen “cost minimization” analysis (CMA). Direct medical costs were calculated 
for 1 patient. In this study were performed 2 variants of ovarian stimulation costs, 
in 1st variant was compared only korifollitropin alfa with ganirelix and follitropin 
alfa with cetrorelix, in 2ndvariant - korifollitropin alfa plus follitropin beta with 
ganirelix and follitropin alfa with cetrorelix. Results: According to published trials 
corifollitropin alfa was a novel and effective treatment option for potential normal 
responder patients undergoing ovarian stimulation with gonadotropin co-treatment 
resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. 
The average cost for 1st variant of a course of korifollitropin alfa with ganirelix was 
34 285 rubles ($ 640), and follitropin alfa with cetrorelix – 65 352 rubles ($ 1 220). The 
average cost for 2nd variant of a course of korifollitropin alfa plus follitropin beta 
with ganirelix was 66 886 rubles ($ 1 249), and follitropin alfa with cetrorelix – 65 
352 rubles ($ 1 220). The CMA has shown that annual savings when used for ovarian 
stimulation 1stvariant without follitropin beta will be 18%. cOnclusiOns: The 
using for ovarian stimulation korifollitropin alfa with ganirelix was more economi-
cally justified treatment option.
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Objectives: To examine the economic burden and health care utilization of 
menopausal women in the U.S. Medicaid population. MethOds: Female patients 
diagnosed with menopausal symptoms and/or those prescribed estrogen hormone 
therapy were identified using the U.S. Medicaid database from 01JUL2008 through 
30JUN2010. The first diagnosis or prescription date was designated as the index date. 
Control patients were identified during the same time period and assigned a ran-
dom index date. Patients in both cohorts were required to be aged 40-65 years and 
have continuous, fee-for-service medical and pharmacy benefits, 6 months pre- and 
post-index date. Controls were matched to cases based on age, state, race and index 
study year. Health care resource utilization and costs during the 6-month follow-up 
period were compared between the menopause and control cohorts. Generalized 
linear models were used to adjust for differences in baseline and demographic char-
acteristics between the cohorts. Results: A total of 71,076 patients were included 
in each cohort. Patients in the menopause cohort were significantly more likely to 
be diagnosed with depression (23.4% vs. 17.3%, p< 0.001) and anxiety (11.6% vs. 8.0%, 
p< 0.001) compared to those in the control cohort. After adjusting for baseline and 
demographic characteristics, significantly more patients in the Menopause Cohort 
had inpatient (10.9% vs. 9.3%, p< 0.001), outpatient hospital (80.6% vs. 34.7%, p< 0.001) 
and physician office visits (89.7% vs. 74.8%, p< 0.001). Higher health care utilizations 
translated to higher health care costs for menopausal patients ($7,237 vs. $6,739, 
p< 0.001) compared to control patients. cOnclusiOns: Patients diagnosed with 
menopausal symptoms or treated with hormone therapy incurred significantly 
higher health care utilization and costs compared to women without menopausal 
symptoms or treatment.
PIH26
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costs. Results: Nexplanon was dominant in the base case and in the majority 
of sensitivity analyses. Nexplanon® allows to avoid 1.6 ‰ pregnancy per year 
over hormonal IUD, 7.3 ‰ over copper IUD and more than 24.7 ‰ over COC with 
savings of 115€ over hormonal IUD, 58€ over copper IUD and more than 868€ 
over COC. At a threshold of 10,000€ per unintended pregnancy avoided, Monte 
Carlo simulations demonstrated an 82.0% probability for Nexplanon® to be the 
most cost-effective method. An alternative analysis was proposed evaluating the 
cost per abortion avoided. In this analysis, the ICER of Nexplanon® versus cop-
per IUD was 8,896€ per abortion avoided while all other methods were strictly 
dominated. cOnclusiOns: Nexplanon® is the most cost-effective strategy when 
compared to other reimbursed contraceptive methods. Additionally, this analysis 
demonstrates that Long-Acting Reversible Contraception (LARC) is dramatically 
more efficient than oral contraception.
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Objectives: Conduct disorders (CD) are common psychiatric disorders in children, 
and place a high burden on the individuals and society. Parenting programs are the 
gold standard for the treatment of CD but little is known about their possible longer-
term cost-effectiveness. The study evaluated the population cost-effectiveness of 
Triple P, the most widely researched parenting program, for the treatment of CD 
in children, from the health sector perspective. This study is part of a series of 
economic evaluations undertaken at the Centre for Research Excellence in Mental 
Health Systems Improvement in Australia. MethOds: A population-based Markov 
model was developed to estimate the cost per disability adjusted life year (DALY) 
averted of Triple P compared with no intervention. The target population was a 
cohort of 5-9 year old children with CD in the 2013 Australian population followed 
through the age of 18 years. Multivariate probabilistic and univariate sensitivity 
analysis were conducted to incorporate uncertainty in the model parameters and 
investigate the impact of assumptions in the outcomes. Results: Triple P was eval-
uated in three formats: Group face-to-face, Self-directed (SD)+telephone assisted, 
and a mixed provision alternative of 50% Group+50% SD+telephone. Group face-
to-face had an incremental cost-effectiveness ratio (ICER) of AU$19 069 per DALY 
averted with a 0.998 probability of cost-effectiveness; SD+telephone had an ICER 
of AU$31 920 per DALY averted with a 0.931 probability of cost-effectiveness; and 
the mixed provision alternative had an ICER of AU$25 494 per DALY averted with a 
0.986 probability of cost-effectiveness. cOnclusiOns: Triple P for the treatment of 
CD is good value for money and should be considered as part of the priority setting 
process in Australia. Group face-to-face Triple P is the most cost-effective option. The 
model will be used for economic evaluations of other interventions targeting CD.
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Objectives: To estimate the cost-effectiveness of the original r-hFSH (Gonal-f) 
when compared with one biosimilar (Bemfola) using the evidence from a head-to-
head registration trial. MethOds: An Excel-based decision-tree model was devel-
oped depicting the different relevant outcomes that result from fertility treatment 
with r-hFSH. Probabilities were populated using the data from a head-to-head trial 
used by the biosimilar for its registration at EMA, using as relevant outcome the 
take-away baby rates found in the trial. Costs were populated from Portuguese 
official sources and include the cost of the two drugs, as well as the costs related 
with treatment, such as costs for IVF, ICSI, child delivery and abortion. The analy-
sis was performed from a societal perspective including only direct medical costs 
with no discounting since all costs occur in a single year. Results: According to 
the model, treatment of 1.000 women with Gonal-f will result in a total number of 
447 pregnancies, with 407 women achieving a new-born child. Total cost for this 
will be 3.062.802,80 € , for a cost per woman achieving a new-born child of 7.534,49 
€ . Respective values for the biossimilar are 361 pregnancies and 321 women with 
new-born children. Total cost for this alternative is 2.957.530,12 € , resulting in a 
cost per new-born child of 9.205,31 € . Incremental cost-effectiveness ratio obtained 
for Gonal-f vs Bemfola is 1.235,32 € per woman with a new-born child. Sensitivity 
analysis did not change the hierarchy in the results except on extreme values. For 
cost-effectiveness ratios to be similar the biosimilar would need a 91% price reduc-
tion. cOnclusiOns: The biossimilar is extendedly dominated by Gonal-f, with 
its cost-effectiveness ratio being higher than the one found for Gonal-f. Under the 
current scenario the use of the biossimilar is not a cost-effective alternative to the 
use of Gonal-f and thus should be avoided.
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Objectives: To estimate the cost-effectiveness of conjugated estrogens/bazedox-
ifene (CE/BZA) compared with conjugated estrogens/medroxyprogesterone (CE/
MPA) or no treatment in a cohort of postmenopausal U.S. women exhibiting vaso-
motor symptoms (VMS), with an intact uterus and at least 12 months since their last 
menses. MethOds: A Markov cohort model was developed to compare CE/BZA with 
CE/MPA or no treatment in terms of costs and Quality Adjusted Life Years (QALYs). 
The model considered VMS, vaginal bleeding, and eight long-term events (LTEs): Hip 
